Previous 10 | Next 10 |
home / stock / veru / veru articles
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing inn...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 ...
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow fin...
MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovati...
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing nove...
MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing nove...
MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing novel me...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...